A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.

被引：29
|
作者：
Finn, Richard S.
Javle, Milind M.
Tan, Benjamin R.
Weekes, Colin D.
Bendell, Johanna C.
Patnaik, Amita
Khan, Gazala Naaz
Laheru, Dan
Anderson, Lisa
Christy-Bittel, Janna Lynn
Barrett, Emma
Guthrie, Kari
Litwiler, Kevin S.
Bekaii-Saab, Tanios S.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Washington Univ, Sch Med, St Louis, MO 63110 USA
[4] Univ Colorado, Canc Ctr, Aurora, CO USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] South Texas Accelerated Res Therapeut START, Ctr Canc Care, San Antonio, TX USA
[7] Univ Michigan Hosp, Ann Arbor, MI USA
[8] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[9] Array BioPharma, Boulder, CO USA
[10] Ohio State Univ, Med Ctr, Columbus, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
220
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer
    R. S. Finn
    D. H. Ahn
    M. M. Javle
    B. R. Tan
    C. D. Weekes
    J. C. Bendell
    A. Patnaik
    G. N. Khan
    D. Laheru
    R. Chavira
    J. Christy-Bittel
    E. Barrett
    M. B. Sawyer
    Tanios S. Bekaii-Saab
    Investigational New Drugs, 2018, 36 : 1037 - 1043
  • [22] A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma
    Van Herpen, C.
    Postow, M. A.
    Carlino, M. S.
    Kalkavan, H.
    Weise, A.
    Amaria, R. N.
    De Vos, F.
    Carvajal, R. D.
    Matano, A.
    Bhansali, S.
    Lam, L.
    Yerramilli-Rao, P.
    Sosman, J. A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S663 - S663
  • [23] Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells
    Yao, Weilong
    Yue, Ping
    Zhang, Guojing
    Owonikoko, Taofeek K.
    Khuri, Fadlo R.
    Sun, Shi-Yong
    CANCER LETTERS, 2015, 364 (01) : 70 - 78
  • [24] Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer
    Doherty, Mark K.
    Tam, Vincent C.
    McNamara, Mairead G.
    Jang, Raymond
    Hedley, David
    Chen, Eric
    Dhani, Neesha
    Tang, Patricia
    Sim, Hao-Wen
    O'Kane, Grainne M.
    DeLuca, Stephanie
    Wang, Lisa
    Pedutem, Theresa
    Knox, Jennifer J.
    BRITISH JOURNAL OF CANCER, 2022, 127 (08) : 1473 - 1478
  • [25] Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer
    Mark K. Doherty
    Vincent C. Tam
    Mairéad G. McNamara
    Raymond Jang
    David Hedley
    Eric Chen
    Neesha Dhani
    Patricia Tang
    Hao-Wen Sim
    Grainne M. O’Kane
    Stephanie DeLuca
    Lisa Wang
    Theresa Pedutem
    Jennifer J. Knox
    British Journal of Cancer, 2022, 127 : 1473 - 1478
  • [26] A proof-of-concept study of MEK inhibitor trametinib monotherapy in patients with biliary tract cancers
    Ioka, T.
    Ikeda, M.
    Fukutomi, A.
    Morizane, C.
    Kasuga, A.
    Takada, R.
    Takahashi, H.
    Todaka, A.
    Okusaka, T.
    Creasy, C.
    Gorman, S.
    Felitsky, D.
    Kawamura, T.
    Kobayashi, M.
    Furuse, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S464 - S464
  • [27] A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer
    Fung, A. S.
    Graham, D. M.
    Chen, E. X.
    Stockley, T. L.
    Zhang, T.
    Le, L. W.
    Albaba, H.
    Pisters, K. M.
    Bradbury, P. A.
    Trinkaus, M.
    Chan, M.
    Arif, S.
    Zurawska, U.
    Rothenstein, J.
    Zawisza, D.
    Effendi, S.
    Gill, S.
    Sawczak, M.
    Law, J. H.
    Leighl, N. B.
    LUNG CANCER, 2021, 157 : 21 - 29
  • [28] A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST).
    Chi, Ping
    Qin, Li-Xuan
    Kelly, Ciara Marie
    D'Angelo, Sandra P.
    Dickson, Mark Andrew
    Gounder, Mrinal M.
    Keohan, Mary Louise
    Movva, Sujana
    Nacev, Benjamin
    Crago, Aimee Marie
    Yoon, Sam S.
    Ulaner, Gary A.
    Martindale, Moriah
    Condy, Mercedes M.
    Biniakewitz, Haley Phelan Matthew
    Singer, Samuel
    Hwang, Sinchun
    Antonescu, Cristina R.
    Tap, William D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST)
    Chi, Ping
    Qin, Li-Xuan
    D'Angelo, Sandra P.
    Dickson, Mark Andrew
    Gounder, Mrinal M.
    Keohan, Mary Louise
    Shoushtari, Alexander Noor
    Condy, Mercedes M.
    Konen, Theresa
    Fruauff, Alana
    DeMatteo, Ronald P.
    Singer, Samuel
    Hwang, Sinchun
    Antonescu, Cristina R.
    Tap, William D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] A phase Ib dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
    Grisham, Rachel N.
    Gordon, Michael S.
    Harb, Wael A.
    Aghajanian, Carol
    McMeekin, D. Scott
    McKinley, Kristin
    Anderson, Lisa Renee
    Chavira, Renae
    Christy-Bittel, Janna
    Barrett, Emma
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345